Clinical Trials Browser

Phase 1/2 × XELOX × 90 days × Clear all

NCT07334431 2026-01-12

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms